Wayne State University
Wayne State University Theses

1-1-2015

Design And Synthesis Of Isatin-Based Caspase
Inhibitors For Ruthenium Caging Applications
Kasun Chinthaka Ratnayake
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_theses
Part of the Biochemistry Commons, and the Organic Chemistry Commons
Recommended Citation
Ratnayake, Kasun Chinthaka, "Design And Synthesis Of Isatin-Based Caspase Inhibitors For Ruthenium Caging Applications"
(2015). Wayne State University Theses. Paper 429.

This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne
State University Theses by an authorized administrator of DigitalCommons@WayneState.

DESIGN AND SYNTHESIS OF ISATIN-BASED CASPASE INHIBITORS FOR
RUTHENIUM CAGING APPLICATIONS
by
KASUN CHINTHAKA RATNAYAKE
THESIS
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
MASTER OF SCIENCE
2015
MAJOR: Chemistry
Approved By:
______________________________
Advisor

Date

DEDICATION

To my loving parents and grandmother
We all have dreams. But in order to make dreams come into reality, it takes a lot of
determination, dedication, self-discipline, and effort

ii

ACKNOWLEDGEMENTS
First, I would like to thank my parents for their unconditional support, love, care,
inspiration and guidance which lead me to the person I am. I would like to thank my loving
grandmother for inspiring me to achieve important things in my life. I would like to convey my
sincere gratitude to my loving wife Ruwani Wasalathanthri for being with me and inspired me
throughout my career.
I wish to thank all members from Kodanko lab who supported me and all undergraduate
students worked during my work in the lab.
I would like to thank Harsha Amarasekara and Danushka Ekanayake for helping me
during my research.
I wish to acknowledge Veronica Lewalski for conducting enzyme inhibition assays and
Dr. Izabela Podorski at School of medicine, Wayne State University for her support given for
enzyme inhibition assays.
I would like to thank my committee members Dr. Mary Kay Pflum and Dr. Tamara
Hendrickson for all the support given.
Last but not least, I would like to thank Dr. Jeremy Kodanko for the inspiration, guidance
and mentorship given throughout my graduate studies. The learning environment in Kodanko lab
helped me to develop my skills. Thank you for all your efforts put on me to mould me as a
skillful and motivated graduate student.
Finally, I would like to thank all who helped me in various ways throughout my graduate
studies at Department of Chemistry, Wayne State University.

iii

TABLE OF CONTENTS

Chapter

Page

DEDICATION .............................................................................................................................................. ii
ACKNOWLEDGEMENTS ......................................................................................................................... iii
LIST OF TABLES ....................................................................................................................................... vi
LIST OF SCHEMES................................................................................................................................... vii
LIST OF FIGURES ................................................................................................................................... viii
LIST OF ABBREVIATIONS ...................................................................................................................... ix
CHAPTER 1 ................................................................................................................................................. 1
1.1 Introduction ......................................................................................................................................... 1
1.1.1 Apoptosis and Caspases ............................................................................................................... 1
1.1.2 Caspase inhibition ........................................................................................................................ 3
1.1.2.1 Natural Caspase inhibitors .................................................................................................... 3
1.1.2.2 Peptidomimetic caspase inhibitors ........................................................................................ 3
1.1.2.3 Caspase-3 inhibitors .............................................................................................................. 8
1.1.2.4 Modified isatin sulfonamides as non-peptidomimetic caspase-3 inhibitors ......................... 8
1.1.3 Ruthenium complexes for caging applications .......................................................................... 13
1.2 Research objectives ........................................................................................................................... 15
CHAPTER 2 ............................................................................................................................................... 16
2.1 Results ............................................................................................................................................... 16
2.1.1 Designing of Caspase-3 inhibitors ............................................................................................. 16

iv

2.2 Synthesis of designed isatin sulfonamide analogs ............................................................................ 17
CHAPTER 3 ............................................................................................................................................... 20
3.1 Conclusion ........................................................................................................................................ 20
3.2 Future directions ............................................................................................................................... 20
3.3 Experimental ..................................................................................................................................... 22
3.3.1 General considerations ............................................................................................................... 22
3.3.2 (S)-5-((2-(methoxymethyl) pyrrolidin-1-yl)sulfonyl)-1-(pyridin-4-ylmethyl)indoline-2,3-dione
(32) ...................................................................................................................................................... 22
3.3.3 (S)-3-(5-((2-(methoxymethyl) pyrrolidin-1-yl)sulfonyl)-2,3-dioxoindolin-1 yl)propanenitrile
(33) ...................................................................................................................................................... 23
REFERENCES ........................................................................................................................................... 29
ABSTRACT................................................................................................................................................ 33
AUTOBIOGRAPHICAL STATEMENT ................................................................................................... 34

v

LIST OF TABLES
Table

Page

TABLE 1-1. Caspase types and classes...............................................................................................2
TABLE 1-2. Inhibition of caspases by peptide aldehydes ..................................................................5
TABLE 1-3. IC50 values for 6 and 8 against different caspases...........................................................7

vi

LIST OF SCHEMES
Scheme

Page

SCHEME 1-1. Mechanism of the peptide bond hydrolysis by cysteine thiol.........................................2
SCHEME 1-2. Thio hemiketal formation of C-3 ketone with cysteine-163 thiol...................................9
SCHEME 2-1. Synthesis route for compound 15...................................................................................17
SCHEME 2-2. Synthesis of 37 as a free base.........................................................................................18
SCHEME 2-3. Synthesis of analog 32...................................................................................................18
SCHEME 2-4. Synthesis of analog 33...................................................................................................18
SCHEME 2-5. Mechanism of formation of 32......................................................................................19
SCHEME 2-6. Mechanism of formation of 33......................................................................................19

vii

LIST OF FIGURES
Figure

Page

FIGURE 1-1. Previously reported tetrapeptide-based caspase-3 inhibitors................................................6
FIGURE 1-2. Caspase-1 inhibtors IDN-6556 and VX-765........................................................................6
FIGURE 1-3. Nitrile-based Caspase inhibitors...........................................................................................7
FIGURE 1-4. IC50 values of 5-nitroisatins as caspase-3 inhibitors.............................................................9
FIGURE 1-5. IC50 values of previously reported caspase-3 inhibitors.......................................................9
FIGURE 1-6. IC50 values of pyrrolidinyl-5-sulfoisatin analogs according to their structural
properties....................................................................................................................................................10
FIGURE 1-7. X-ray crystallographic data of 21 bound within the active site of caspase-3......................11
FIGURE 1-8. Enzyme binding pockets and binding site of isatin analog 21............................................11
FIGURE 1-9. Previously reported Ki values of pyrrolidinyl-5-sulfoisatin analogs with caspase-3..........13
FIGURE 1-10. Previously reported photocagable biologically active compounds..................................14
FIGURE 1-11. Chemical structures of caged ruthenium complexes.........................................................15
FIGURE 2-1. Proposed pyrrolidinyl-5-sulfoisatin analogs for caging studies..........................................16
FIGURE 3-1. 1H-NMR spectrum of 32......................................................................................................25
FIGURE 3-2. 13C-NMR spectrum of 32.....................................................................................................26
FIGURE 3-3. 1H-NMR spectrum of 33......................................................................................................27
FIGURE 3-4. 13C-NMR spectrum of 33.....................................................................................................28

viii

LIST OF ABBREVIATIONS
Caspases: Cysteinyl dependent Aspartate directed Specific Proteases
Boc-D-FMK: t-Butoxycarbonyl-Asp-fluoromethylketone
Z-VAD-FMK: Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
FACS: Fluorescence Activated Cell Sorter
OA: Osteoarthritis
Ru: Ruthenium
bpy: Bipyridine
terpy: Terpyridine
DMF: Dimethyl formamide
DMSO: Dimethyl sulfoxide
DIPEA: Diisopropylethylamine
THF: Tetrahydrofuran
CHCl3: Chloroform
ESI-TOF: Electrospray ionization - time of flight
NMR: Nuclear Magnetic Resonance
FT-IR: Fourier Transform Infrared

ix

1

CHAPTER 1
DESIGN AND SYNTHESIS OF ISATIN-BASED CASPASE INHIBITORS FOR
RUTHENIUM CAGING APPLICATIONS
1.1 Introduction
1.1.1 Apoptosis and Caspases
Apoptosis is a process of cell degradation in eukaryotes. This process is mediated by
specific signaling cascades. The ultimate result of apoptosis is programmed cell death. This
significant cellular process is directly co-related with embryogenesis, the immune system, ageing
and various diseases including cancers, ischemic vascular diseases and neurodegenerative
disorders such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.1
An intracellular proteolytic cascade is involved in regulating apoptosis. This process
depends on a protease enzyme class called caspases (cysteinyl dependent aspartate directed
specific proteases). Caspases exist as inactive proenzymes (called zymogens) that are activated
via proteolytic pathways to form two subunits. A characteristic feature of caspases is the
presence of cysteine and histidine residues in the active site. These amino acids carry out
cleavage of the peptide bond next to aspartic acid residues. The reaction mechanism of peptide
hydrolysis is shown below (Figure 1-1). The cleaved peptide sequence is designated as an amino
acid chain Pn-P3-P2-P1-P1’-P2’-P3’-Pn’ and its corresponding substrate binding site is designated
as Sn-S3-S2-S1-S1’-S2’-S3’-Sn’.2 Caspases have a unique preference for aspartic acid at P1 that
binds specifically to the S1 subsite. Caspases specifically cleave the peptide from its C-terminal
next to this aspartic acid. The catalytic efficiency is drastically reduced if a different amino acid
is substituted at P1 in the substrate. The cleavage preference for aspartic acid over glutamic acid
in the S1 subsite is more than 20,000 fold.3 It is also reported that the S3 subsite prefers glutamine
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residue in all mammalian caspases. Therefore, the specific tetrapeptide sequence can be
identified as X-Glu-X-Asp for mammalian caspases.2

Scheme 1-1: Mechanism of the peptide bond hydrolysis by cysteine thiol

Caspases are divided into different classes according to their roles in the signaling
cascades of apoptosis (Table 1-1). Caspases 6, 8, 9 and 10 are initiators and found at the
beginning of the signaling cascade. Those caspases activate the effector caspases. Caspases 2, 3
and 7 are executioner/effector caspases which are found downstream in the signaling cascade.4
Caspases 1, 4, 5 and 13 are involved in inflammation and they are not active in the cell death
process. Caspases 2, 3 and 7 are the most significant and studied caspase types because they are
involved in almost all apoptotic models.5
Table 1-1. Caspase types and classes
Enzyme class

Caspase type

1- Initiators

6, 8, 9, 10

2- Executioners

2, 3, 7

3- Inflammation

1, 4, 5, 13

3

1.1.2 Caspase inhibition
Extensive research has been conducted on caspases and their pharmacological activity
because they are important targets in drug discovery.2-8 Development of novel caspase inhibitors
is attractive medicinally and pharmaceutically to prevent diseases caused by dysregulated
apoptosis. Caspase inhibitors can be categorized as natural and synthetic inhibitors. Natural
inhibitors are sub-categorized as viral and cellular caspase inhibitors. Synthetic inhibitors are
based on peptidomimetic and non-peptidyl compounds.7
1.1.2.1 Natural Caspase inhibitors

Previous studies showed the involvement of viral and cellular caspase inhibitors in
apoptosis. For example, Cytokine Response modifier A (CrmA), a product of cowpox virus and
a member of the serpin superfamily of protease inhibitors, has been identified as a Caspase-1
inhibitor. A baculoviral protein, p35, is an inhibitor for both insect and mammalian caspases.
Mammalian caspase inhibitors such as Survivin and XIAP are reported as specific caspase-3
inhibitors.7
Various synthetic caspase inhibitors have also been reported.6-14 Development of
synthetic caspase inhibitors is important to gain specificity in caspase inhibition. These inhibitors
are categorized as either peptide and non-peptide-based compounds.
1.1.2.2 Peptidomimetic caspase inhibitors
Peptidomimetic caspase inhibitors have been developed according to their structural
properties and interactions with the substrate cleavage sites of caspases. Caspases identify
specific binding regions of peptide substrates according to the peptide sequence of the substrate.
Caspases preferentially cleave the peptide bonds next to aspartate residues due to the stability
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caspases gain from interactions of cysteine and histidine residues in the active binding region.
Thus, an aspartate is typically included at the P1 position in most peptidic inhibitors.
Various caspase inhibitors have been reported which inhibit different caspases.6 For
example Ac-YVAD-CHO is a potent caspase-1 inhibitor which prevents release of interleukin1β (IL-1β) from monocytes. Peptide-based caspase inhibitors can be categorized according to the
number of aspartyl residues present in the peptide and the number of peptide units present in the
compound.7 For example Boc-Asp-fluoromethylketone (Boc-D-FMK) is a broad-range caspase
inhibitor containing a single aspartyl residue. Z-VAD-FMK is a tri-peptide that competitively
and irreversibly inhibits caspases 1-10.7 Tetrapeptides have also been developed and their
structures are significant for substrate specificity. The tetrapeptide inhibitors generally have
higher potency against caspases because they contain a tetrapeptide region which is specifically
recognized by the enzyme (Table 1-2).6,7
According to previously reported caspase inhibition data (Table 1-2), the significance of
peptide aldehyde sequences has been established. For example, Ac-WEHD-CHO 1 specifically
binds to group I caspases and Ac-DEVD-CHO 2 binds with group II caspases.
Peptide aldehydes such as Ac-WEHD-CHO 1, Ac-DEVD-CHO 2, Boc-IETD-CHO 3 and
Boc-AEVD-CHO 4 are caspase-3 inhibitors (Figure 1-1).6,7 The specificity of these inhibitors for
different caspases has been desired for many years. Halomethyl ketone containing peptide
derivatives are highly reactive irreversible inhibitors. Thus they lack specificity towards a
specific caspase. Peptides containing aldehyde, ketone and nitrile groups are reversible inhibitors
of caspases.11 Some peptide-based caspase inhibitors have not shown good efficacy (IC50 < 1
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µM) in cellular apoptotic models.6-8 Lower cell permeability of these peptidyl inhibitors limits
the efficacy. Thus, use of peptidyl compounds as caspase inhibitors in vitro is limited.
Table 1-2. Inhibition of caspases by peptide aldehydes6
Enzyme

Aldehyde Ki (nM)
WEHD

YVAD

DEVD

IETD

AEVD

Caspase-1

0.056

0.76

18

<6

<12

Caspase-4

97

362

132

400

375

Caspase-5

43

163

205

223

438

Caspase-3

1960

>10,000

0.23

195

42

Caspase-7

>10,000

>10,000

1.6

3280

425

Caspase-2

>10,000

>10,000

1710

9400

>10,000

Caspase-6

3090

>10,000

31

5.6

52

Caspase-8

21.1

352

0.92

1.05

1.6

Caspase-9

508

970

60

108

48

Caspase-10

330

408

12

27

320

Group I

Group II

Group III

Amino acid sequences are shown as Ac-XXXX-CHO (Refer Figure 1-1 for structures)

6

1

2

>50 µM

1 µM

3

4

>50 µM

0.6 µM

Figure 1-1: Previously reported tetrapeptide-based caspase-3 inhibitors

Research has been conducted to develop peptidomimetic caspase inhibitors to increase
their potencies and selectivities against specific caspases. Peptidomimetic caspase-1 inhibitors
such as IDN-6556 and VX-765 are already being investigated in clinical trials (Figure 1-2).10

Figure 1-2: Caspase-1 inhibitors IDN-6556 and VX-765

Prodrug VX-765 has been used to design nitrile based peptidomimetic caspase inhibitors
using SAR studies (Figure 1-3).11 For example, compounds 6 and 8 have reported IC50 values of
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2.58 nM and 0.023 nM against caspase-1, respectively. Compounds 6 and 8 show different
potencies against other caspases (Table 1-3).

5

6

7

8

Figure 1-3: Nitrile-based Caspase inhibitors

Table 1-3. IC50 values for 6 and 8 against different caspases11
Compound

Caspase type, nM
1

3

4

5

6

7

8

9

10

14

6

2.58

>10000

1380

1300

>10000

>10000

>10000

91.5

>10000

>10000

8

0.023

>10000

13.8

3.60

>10000

>10000

25.2

2.17

89.7

801

Later studies revealed that a greater selectivity and efficacy could be achieved using nonpeptidomimetic compounds as caspase inhibitors.9-14 Molecular modeling with computational
studies has been used to design potent small molecular caspase inhibitors.14,15 Structure activity
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relationship studies have also been conducted in order to develop highly potent and specific
caspase inhibitors. Small molecular caspase inhibitors have shown greater specificity towards
various caspases than peptidomimetic inhibitors. These inhibitors contain various functional
groups such as isoquinoline, sulfonamide and nitriles.9,13,14
1.1.2.3 Caspase-3 inhibitors
Caspase-3 is one of the executioner caspases frequently involved in most
pharmacological models of apoptosis and their signaling cascades. It is known to be activated in
most of the apoptotic cellular processes.5 Therefore caspase-3 is a significant molecular target for
studying apoptosis and its functions. Selective caspase-3 inhibitors have potential as therapeutic
agents. Isatin- and isoquinoline-based caspase-3 inhibitors have been reported.9,13-17 Some of the
reported caspase-3 inhibitors have been further investigated in preclinical studies.10
1.1.2.4 Modified isatin sulfonamides as non-peptidomimetic caspase-3 inhibitors

In 2000, SmithKline Beecham conducted a high-throughput screen using their compound
library in order to identify non-peptidic small molecules that inhibit caspase-3.14 Several 5nitroisatins were identified (Figure 1-4). Later studies showed that the presence of electronwithdrawing groups (EWG) such as nitro and cyano groups were necessary for higher potency.13
The higher potency is attributed to the interaction of the active site cysteine thiol with the C-3
ketone of isatin. The thiol-ketone interaction is enhanced upon increasing the electrophilicity of
C-3 (Scheme 1-2). Thus, an EWG at C-5 of isatin is required for higher inhibition, which makes
the C-3 more susceptible for nucleophilic attack. Compounds 9 and 14 contain EWGs such as
nitro and cyano on C-5 and show higher potency against caspase-3. Compound 13 has a
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carboxylate group at C-5, which limits the electrophilicity of C-3 and shows lower potency
(Figure 1-5).

9
3 µM

10

11

1 µM

0.25 µM

Figure 1-4. IC50 values of 5-nitroisatins as caspase-3 inhibitors14

Scheme 1-2. Thio hemiketal formation between C-3 ketone and cysteine-163 thiol

12
>50 µM

9
1 µM

13

14

>50 µM

0.6 µM

Figure 1-5. IC50 values of previously reported caspase-3 inhibitors13

Use of 5-N,N-dialkylisatin sulfonamides as potential caspase-3 inhibitors has been
investigated.13,14 The nitro group at C-5 has been substituted with a 5-sulfonamide group to
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increase metabolic stability. Different amine substituents have also been used to investigate the
caspase-3 potency and found that the incorporation of a pyrrolidine moiety is favorable for
higher potency (Figure 1-6).13 The stereochemistry of this pyrrolidine moiety (15 and 17), cyclic
vs acyclic structures (15 and 19), and ring sizes (16, 18 and 20) have been examined in inhibition
studies. Incorporation of an S-2-methoxymethyl group in the pyrrolidine ring (15) yields a higher
potency than its enantiomer, R-2-methoxymethyl (17). The ring size of pyrrolidine does not
significantly change the potency (16, 18 and 20). The acyclic analog of the pyrrolidine moiety
(19) is less potent than its cyclic analog (15).13

15
120 nM

16
2,800 nM

18
17
18,000 nM

2,200 nM

19

20

910 nM

1,900 nM

Figure 1-6. IC50 values of Pyrrolidinyl-5-sulfoisatin analogs against caspase-3 according to their
structural properties13
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Isatin sulfonamides inhibits executioner caspases (caspase-3 and -7).13 In 2000, X-ray
crystallographic data of caspase-3 bound with an isatin analog, 1-methyl-5-(2-phenoxymethylpyrrolidine-1-sulfonyl)-1h-indole-2,3-dione 21 in the active site of the enzyme were reported
(Figure 1-7).14 Some key interactions between the inhibitor and caspase-3 were identified.
Formation of a tetrahedral thio hemiketal intermediate was observed between the thiol of
cysteine-163 and the C-3 ketone of 21. Interaction with His-121 was also observed. Hydrophobic
interactions occurred between the S2 pocket and the pyrrolidine ring of 21. A hydrophobic
interaction of Tyr-204 with one face of the isatin core enhances the binding of inhibitor (Figure
1-7 and Figure 1-8).14

His-121

Tyr-204

Cys-163

Figure 1-7. X-ray crystallographic data of 21 bound within active site of caspase-314

Figure 1-8. Enzyme binding pockets and binding site of isatin analog 21

12

Modifying isatin sulfonamide analogues with pyrrolidine groups has significant effects
on caspase inhibition.13 For example, various pyrrolidinyl-5-sulfoisatins inhibit caspase-3 and -7
(Figure 1-9). Isatin sulfonamide analogs were modified according to structure activity
relationships and their potencies in cellular apoptosis assays were determined. The inhibition of
executioner caspases (caspase-3 and -7) is critical to prevent apoptosis in multiple cell types.
Human Jurkat T cells and chondrocyte cells have been used to evaluate the cell death process in
a previous study.13 FACS (Fluorescence Activated Cell Sorter) analysis was used to investigate
camptothecin-induced apoptosis in Jurkat and chondrocyte cells. Compound 15 inhibited
apoptosis of Jurkat cell by 54% at 50 µM which was in good correlation with in vitro studies.13
Chondrocyte apoptosis was investigated because of its relevance to osteoarthritis (OA).
Osteoarthritis is a degenerative joint disease in which erosion of articular cartilage occurs.
Chondrocytes, the only cell type specific to cartilage tissue, are a good candidate to monitor
increased levels of apoptosis. A gene, bcl-2 is involved in apoptosis has been highly expressed in
chondrocytes adjacent to OA lesions. The fibrillar collagen network is degraded upon
progression of OA. Thus, chondrocyte cell death is increased.13 Similar results were obtained for
compound 15 for inhibition of chrondocyte apoptosis which showed 98% inhibition at 50 µM.
Recent cell apoptosis studies show that modified isatin sulfonamide analogs inhibit apoptosis in
human umbilical vein endothelial cells (HUVEC).17 Western blot analysis indicates the cleavage
of a general caspase substrate PARP (poly ADP ribose polymerase), which correlates with
caspase activity in cellular apoptosis.13,17 PARP is a well known DNA repair enzyme and a
substrate for caspase-3 cleavage in cellular apoptosis.12 PARP is cleaved into 29 kDa and 85 kDa
subunits by caspase-3 during apoptosis and cleavage can be monitored using Western blot
analysis. This analysis has been extensively used in research to monitor cellular apoptosis.
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The 2-phenoxymethyl pyrrolidinyls did not show cellular apoptosis inhibition activity up
to 300 µM and are less potent than 2-methoxymethyl pyrrolidinyl compounds.17 This observation
implies that phenoxymethyl pyrollidinyls (24) have lower cell penetration properties17 than that
of methoxymethyl pyrollidinyls. The lipophilicity of these compounds is a major factor for their
cell penetration properties. These properties were taken into account in the designing process of
pyrollidinyl sulfo isatins as caspase-3 inhibitors.13-17

15
41.8 nM

23
8.3 nM

22
1.2 nM

24
56.1 nM

Figure 1-9. Previously reported Ki values of pyrrolidinyl-5-sulfoisatin analogs with caspase-317

1.1.3 Ruthenium complexes for caging applications
Metal complexes are important therapeutics and tools for biological applications.18-31 The
caging of biologically active molecules with metal complexes has been explored recently.31-35
Photocaging is an established method in biological and medicinal research. It enhances our
ability to investigate living systems by providing spatial and temporal control over the release of
the biologically active molecules.31-35
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Ruthenium compounds have been used to develop caged complexes for several reasons.
Ru-based compounds have unique photochemical properties which allow photoreactions to
proceed with visible light, which is less harmful towards biological systems than UV light.
Various biologically active compounds have been caged with Ru-complexes.31-35 Those bioactive compounds contain functional groups that cannot be caged with organic photolabile
groups. Recently reported bioactive molecules contain nitriles, N-containing heteroaromatics and
thioethers that strongly bind to the metal center. Recently, neuroactive biomolecules (4aminopyridine 25)

31-33

, bio-active thioethers34 (D-biotin 26 and N-acetyl-L-methionine 27) as

well as small molecular enzyme inhibitors (28)35 have been reported to be caged with these Rubased complexes (Figure 1-10). A long-term goal of compounds like these is to achieve spatial
and temporal release over drug release that could be used to treat various diseases.

25

27

26

28

Figure 1-10. Previously reported photocagable biologically active compounds

Ruthenium polypyridyl compounds are excellent candidates for caging of small
molecules. Various ruthenium polypyridyl groups have also been developed as efficient caging
groups. The complexes Ru(bpy)2 (bpy = 2,2’-bipyridne) (29, 30) and Ru(terpy)(bpy) (31) are

15

leading examples.31-35 They show attractive photochemical properties, including stability in the
dark and efficient release upon irradiation with visible light. Importantly, their Ru-caged
byproducts show low toxicity. These Ru-polypyridyl complexes consist of planar heteroaromatic
ligands with highly conjugated, extended π-electron systems that enhance their photolabile
properties (Figure 1-11).

30

29

31

Figure 1-11: Chemical structures of caged ruthenium complexes

1.2 Research objectives

The aim of this study is to develop novel caspase-3 inhibitors which can be caged with
ruthenium complexes. These light activated Ru complexes can then be used as tools for chemical
biology and as potential therapeutics. Development of light activated compounds has advantages
when compared to general small molecules. A unique advantage of light activation is the ability
to control time, location and concentration of the biologically active compounds in vitro and in
vivo. Therefore, light activated caspase-3 inhibitors could be used as a chemical tool to block
apoptotic induction at specific sites in vivo. In the long term, the spatial and temporal control
could be used to treat various diseases caused by dysregulation of apoptosis.

16

CHAPTER 2
2.1 Results
2.1.1 Designing of Caspase-3 inhibitors
The novel caspase-3 inhibitors developed in this study were designed based on several
factors. Recent studies show that various 5-pyrrolidinylsulfonyl isatins act as caspase-3
inhibitors. Thus, we decided to design compounds based on a 5-pyrrolidinylsulfonyl isatin core.
This small molecule inhibitor could be modified accordingly to develop light activated
ruthenium complexes. Higher caspase-3 inhibition was desired in the designing process. Several
findings in previous studies were considered when designing high potent caspase-3
inhibitors.13,15-17 Use of specific stereochemistry in the pyrrolidine moiety is important since Salkoxypyrrolidine is more potent than its R-stereoisomer against caspase-3. Methoxymethyl
pyrrolidinyl analogs show higher cell permeability and lower lipophilicity than phenoxymethyl
pyrrolidines, thus methoxymethyl pyrrolidine analogs were chosen for further studies. When
designing the ruthenium-caged inhibitors, the chosen analogs should contain a group that has
caging and photolabile properties. Therefore, pyridyl and cyano groups were introduced into
these isatin sulfonamide analogs. Therefore 4-methylpyridine and cyanoethyl groups were
selected to be attached to the N-1 position, resulting in compounds 32 and 33 (Figure 2-1).

32

33

Figure 2-1. Proposed pyrrolidinyl-5-sulfoisatin analogs for caging studies
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2.2 Synthesis of designed isatin sulfonamide analogs
The designed analogs were synthesized using literature and modified procedures13-17, 36-39
(Scheme 2-1). Compound 15 was synthesized as the precursor for the final analogs 32 and 33.
First, isatin was sulfonated at its C-5 position using fuming sulfuric acid containing 20% SO3 to
obtain 34. Then according to the procedure reported previously,17 5-chlorosulfonyl isatin 35 was
synthesized. The procedure was optimized to increase the yield. The condensation of 35 with 36
was performed in a 1:1 CHCl3/THF solvent system in the presence of diisopropylethylamine
(DIPEA). The reaction from 35 to 15 was challenging because 15 has lower solubility in most of
the solvents thus giving low yields for 15. Compound 15 was purified and isolated using flash
column chromatography in 45% yield.

34

35
15

36
Scheme 2-1. Synthesis route for compound 15

Compounds 32 and 33 were synthesized using modified and optimized procedures
(Scheme 2-3 and Scheme 2-4). Compound 32 was synthesized using N-alkylation of 15 with 4bromomethylpyridine (37). In this reaction compound 37 needed to be used as a free base
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(Scheme 2-2) to avoid formation of an undesired side products which could lower yield of 32.
The synthesis of 33 proceeds through a base-catalyzed addition reaction of 15 with acrylonitrile.
The reason for the low yield obtained for 33 might be the formation of polymers with
acrylonitrile, consistent with TLC analysis which showed a complex mixture of products. The
proposed reaction mechanisms for the formation of 32 and 33 are outlined below (Scheme 2-5
and Scheme 2-6).

37
Scheme 2-2. Synthesis of 37 as a free base
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32

37
Scheme 2-3. Synthesis of analog 32

15

33
Scheme 2-4. Synthesis of analog 33

Inhibition studies were done on 32 and 33 with human recombinant caspase-3. These
enzyme inhibition assays were performed by the undergraduate researcher Veronica Lewalski.
IC50 values were calculated according to the enzyme inhibition data. Compound 32 showed an
IC50 of 89 nM and 33 showed IC50 of 560 nM.40
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І
32

15
37
Scheme 2-5. Mechanism for formation of 32

І
15

33

IІ

Scheme 2-6. Mechanism for formation of 33
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CHAPTER 3
3.1 Conclusion
The novel compounds 32 and 33 were synthesized successfully and their inhibitory
effects were studied. The compounds 32 and 33 were both potent inhibitors of caspase-3.
Compound 32 was more potent than compound 33. Thus compound 32 was selected for further
ruthenium caging studies.
3.2 Future directions
The designed compound 32 is expected to be caged with ruthenium polypyridyl
complexes. The caged ruthenium complexes will be subjected to light activation experiments
where the IC50 values of caged complexes under light and dark conditions will be determined
and compared. Higher stability and lower potency will be desired for caged Ru-complexes in
dark conditions. A higher dark/light inhibition ratio is desired and expected for 32. Then
photoinduced cell toxicity studies could be performed with these ruthenium caged complexes to
monitor caspases-3 inhibition in different cell models. Cellular models of apoptosis such as
Jurkat cells, chondrocytes, neutrophils from mouse bone marrow and HUVEC cells can be used
to evaluate cellular toxicities of the designed compounds.
The spatial and temporal controlling experiments could be done for the developed Rucomplexes in various biological systems and animal models and apoptosis in these systems could
be monitored. The reduction of the cellular apoptosis is desired upon light activation of these Rucaged complexes. The cellular death could be monitored using various imaging methods. These
combined experiments and results could lead to the development of novel tools to treat
dysregulated apoptosis in biological systems that can be used to prevent various diseases. For
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example, in vivo experiments could be carried out to study cardiomyocyte apoptosis (in
myocardial ischemia model) and evaluate the heart muscle and tissue damage in mouse models.
These designed compounds can also be used to evaluate apoptosis in bacterial meningitis models
to study neuronal cell degaradation and also in hepatitic models to study liver damage in mouse
models. These experiments could be carried out to develop efficient therapeutic methods such as
photodynamic therapy to treat diseases caused by apoptosis.
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3.3 Experimental
3.3.1 General considerations
All reagents were purchased from commercial suppliers and used as received. NMR
spectra were recorded on a Varian FT-NMR Mercury-400 Spectrometer. IR spectra were
recorded on a Bruker Tensor 27 FT-IR spectrophotometer (KBr pellet). High resolution (HRMS)
electrospray (ESI-TOF) mass spectra were recorded on a Micromass LCT spectrometer. Melting
points were recorded on Thermo scientific 9100 melting point apparatus. Enzymatic assays were
performed on a Tecan Infinite F200Pro microplate reader. All reactions were performed under
ambient atmosphere unless otherwise noted. Anaerobic reactions were performed by purging the
reaction solutions with Ar or N2.
3.3.2 (S)-5-((2-(methoxymethyl) pyrrolidin-1-yl)sulfonyl)-1-(pyridin-4-ylmethyl)indoline2,3-dione (32)
32

To a stirred solution of 15 (0.936 g, 2.89 mmol) in DMF (40 mL), 60% NaH in mineral oil
(0.174 g, 7.23 mmol) was added at 0 °C. The reaction was stirred for 30 min under Ar
atmosphere. Then a solution of 4-bromomethyl pyridine 37 was prepared as follows. 4bromomethyl pyridine hydrobromide salt (0.873 g, 3.46 mmol) was dissolved in DMF (15 mL)
and Na2CO3 (0.367 g, 3.46 mmol) was added and stirred for 10 min. The filtrate of 37 was added
dropwise to the reaction mixture over 10 min and stirred for additional 4 h at 0 °C under Ar
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atmosphere. The reaction was diluted with EtOAc (60 mL) and washed with saturated aqueous
NaCl (3 × 40 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated in
vacuo. The crude product was purified by silica gel chromatography using 1% MeOH:CH2Cl2
solvent system. The isolated fractions containing product were combined and concentrated in
vacuo and further crystallized using EtOAc:hexanes. The product was isolated as a bright yellow
solid. Yield: 0.730 g (1.76 mmol, 61%). mp = 172-174 °C. 1H NMR (400 MHz, DMSO): δ 8.51
(d, 2H, J = 4.4 Hz), 8.01 (d, 1H, J = 8.4 Hz), 7.84 (s, 1H), 7.46 (d, 2H, J = 4.4 Hz), 7.08 (d, 1H, J
= 8.0 Hz), 4.99 (s, 2H), 3.67 (m, 1H), 3.41 (dd, 1H, J = 9.6 Hz, 3.6 Hz), 3.32 (s, 3H), 3.26 (t,
2H), 3.06 (m, 1H), 1.73 (m, 2H), 1.48 (m, 2H).
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C NMR (100 MHz, DMSO): δ 181.7, 159.2,

153.3, 150.2, 144.8, 136.9, 132.3, 123.1, 122.6, 118.9, 111.8, 74.9, 59.1, 58.9, 49.4, 42.7, 28.7,
24.0. IR (νmax) (KBr): 3443, 2929, 2361, 2342, 1747, 1616, 1478, 1450, 1417, 1365, 1344, 1330,
1199, 1181, 1154, 1130, 1115, 1070, 1041, 994. HRMS (ESI-TOF): calc’d for C21H25N3O6NaS
(M+MeOH+Na)+ 470.1362, found: 470.1339.
3.3.3 (S)-3-(5-((2-(methoxymethyl) pyrrolidin-1-yl)sulfonyl)-2,3-dioxoindolin-1
yl)propanenitrile (33)
33

To a stirred solution of 15 (0.200 g, 0.620 mmol) in DMF (10 mL), KOH (0.004 g, 0.062 mmol)
was added and stirred for 10 min at RT. Then acrylonitrile (45 µL, 0.68 mmol) was added
dropwise and stirred for 2 days at RT under Ar atmosphere. The reaction mixture was added to
H2O (30 mL), and extracted with EtOAc (3 × 20 mL). The combined organic layer was washed

24

with 10% aqueous NaCl (3 × 20 mL). The organic layer was dried over anhydrous Na2SO4 and
concentrated in vacuo. The crude product was purified by silica gel chromatography with 1%
MeOH:CH2Cl2 to afford a yellowish-orange solid. Yield: 0.064 g (0.169 mmol, 27%). mp = 134138 °C. 1H NMR (400 MHz, CDCl3): δ 8.15 (d, 1H, J = 2 Hz, 8.4 Hz), 8.11 (d, 1H, J = 2 Hz),
7.19 (d, 1H, J = 8.0 Hz), 4.10 (t, 2H), 3.77 (m, 1H), 3.57 (dd, 1H, J = 4.0 Hz, 9.2 Hz), 3.43 (m,
1H), 3.38 (d, 1H, J = 2.4 Hz, 10 Hz), 3.36 (s,3H), 3.14 (m, 1H), 2.86 (t, 2H), 1.92 (m, 2H), 1.69
(m, 2H). 13C NMR (100 MHz, CDCl3): δ 180.8, 157.8, 152.3, 137.6, 134.7, 124.9, 117.5, 116.8,
110.4, 74.8, 59.3, 59.1, 49.4, 36.8, 28.8, 24.1, 16.7. IR (νmax) (KBr): 3422, 2921, 2852, 2361,
2251, 1742, 1717, 1647, 1612, 1558, 1542, 1508, 1475, 1456, 1418, 1373, 1364, 1340, 1314,
1268, 1234, 1195, 1175, 1153, 1133, 1063, 1046, 991, 970, 905, 877. HRMS (ESI-TOF): calc’d
for C17H19N3O5NaS (M+Na)+ 400.0943, found: 400.0958.
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32

Figure 3-1: 1H-NMR spectrum of 32
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32

Figure 3-2: 13C-NMR spectrum of 32
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33

Figure 3-3: 1H-NMR spectrum of 33
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33

Figure 3-4: 13C-NMR spectrum of 33
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ABSTRACT
DESIGN AND SYNTHESIS OF ISATIN BASED CASPASE INHIBITORS FOR
RUTHENIUM CAGING APPLICATIONS
by
KASUN CHINTHAKA RATNAYAKE
August 2015
Advisor: Jeremy J. Kodanko, Ph.D.
Major: Chemistry (Organic)
Degree: Master of Science
Apoptosis is the energy dependent programmed cell death. Improper function of
apoptosis could lead to diseases such as cancers, strokes, Alziemer’s disease. Caspases are the
enzymes involved in the later stage of this process. Peptidyl and non-peptidyl caspase inhibitors
have been synthesized recently. These non-peptidyl compound classes which consist of
pyrrolidinyl-5-sulfo isatins have showed a greater potency against executioner caspases, caspase3 and -7. According to literature and for further caging studies, two compounds were designed,
synthesized and evaluated their inhibition against caspase-3 in this study. The analog in which its
N-1 position alkylated with a 4-methyl pyridine moiety (32) showed higher inhibition than the
analog in which N-1 was alkylated with cyanoethyl group (33). Thus, compound 32 was selected
for further caging studies with ruthenium.
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